CrushSCI.com
52.8Average days
54.5Median days
2Fastest days
98Longest days
7462025 publications

Paper Review Records

All Paper Review Records

6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

98 days

Clonal hematopoiesis in autoimmune hemolytic anemia

Authors
Stennio Da Silva Faria; Rafaël Moisan; Estelle Lecluze; Thomas PincezShow moreShow less
Affiliations
1. CHU Sainte-Justine Azrieli Research Center, Montréal, QC, Canada; 2. Faculty of Medicine, Université de Montréal, Montréal, QC, Canada; 3. Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Montréal, QC, CanadaShow moreShow less
Source PDF DOI Publisher page
2 days

Gene therapy for sickle cell disease durability

Authors
Chattip Prueksapraopong; Donald B. KohnShow moreShow less
Affiliations
1. Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CAShow moreShow less
Source PDF DOI Publisher page
14 days

Defining durability in SCD gene therapy

Authors
Naif I. AljohaniShow moreShow less
Affiliations
1. Department of Oncology, Adult Hematology, and Stem Cell Transplantation, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi ArabiaShow moreShow less
Source PDF DOI Publisher page
51 days

ASH clinical practice guidelines: evaluation of discordance between certainty of evidence and strength of recommendations

Authors
Samantha A. Hershenfeld; Robert Kunkle; Menaka Pai; Adam Cuker; Matthew C. CheungShow moreShow less
Affiliations
1. 1Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; 2. 2American Society of Hematology, Washington, DC; 3. 3Department of Medicine, McMaster University, Hamilton, Canada; 4. 4Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 5. 5Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PAShow moreShow less
Source PDF DOI Publisher page
58 days

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy

Authors
Jean-Roch Le Henaff; Loïc Le Guennec; Pauline Schiro; Kevin Bihan; Jacques Gasnault; Bruno Stankoff; Yassine Taoufik; Emmanuel Treiner; Danièle Bensoussan; Sébastien Lhomme; Anne-Sophie L’Honneur; Fabrice Bonneville; Natalia Shor; Valérie Pourcher; Béatrice Pignolet; Baptiste Lievin; Clément Javaux; Julien Le Guen; Eolia Brissot; Pierre-Antoine Limouzin; Clémence Richaud; Bruno Lioure; Thomas Wirth; Paul Petitgas; Simon Herbel; François Coustillères; Elena-Camelia Rusu; Laura Maerten; Aurore Perrot; Agnès Sommet; Damien Roos-Weil; Margaux Lafaurie; Nicolas Weiss; Guillaume Martin-Blondel; P. Rispal; R. Dhersin; V. Dubée; J. Paillassa; A.S. Valadoux; E. Piet; S. Arista; S. Ancellin; O. Paccoud; A. Serris; F. Lanternier; C. Duvivier; C. Vignals; F. Lantier; V. Delcey; A. Moussiegt; M. El Soudany; D. Brebant; I. Charachon; M. Gilbert; X. Lescure; S. Lariven; B. Denis; E. Rubenstein; C. Barsan; R. Ursu Billot; N. Crainic; F. Mechai; S. Abad; R. Courtois; A. Durrbach; C. Cauquil; Y. Quertainmont; J. Pacanowski; A. Capes; A. Banet; Q. Richier; O. Heinzlef; A. De la Selle; A.L. Houist; G. Melica; W. Vindrios; V. Esnault; M. Mahevas; G. Volle; E. Mortier; F. Finet; N. Mele; A. Chabrol; M.E. Vekemans; C. De la Porte; C. Batot; E. Chaugne; Y. Beigneux; J. Garcia; M. Dorel; J. Sarrabere; C. Tivenez; H. Chaussade; M. Mehlen; C. Cazanave; F. Dauchy; C. Vignals; E. Forcade; C. Bellissard; W. Meissner; L. Hobeika; M. Pinel; T. Sooltangos; K. Abdelmoumen; F. Bourdain; P. Da Silva; P. Gazeau; R. Paret; D. Marechal; F.M. Merrien; E. Legras; M. Tore; C. Theis; O. Tournilhac; M. Raquin; A. Zaghdoudi; S. Abidh; S. Sire; H. Frahier; G. Ahle; F. Medina; M. Blot; V. Viziolo; I. Aouissi; L. Elmansouf; G. Gaube; A. Leurs; C. Lesoil-Markowski; J. Poupart; E. Laborde; O. Epaulard; M. Le Maréchal; G. Wuillaume; O. Casez; C. Lahuna; S. Markowicz; K. Schepers; S. Devatine; T. Dequidt; T. Coman; F. Andry; A. Thomas; E. Durand; C. Badr; T. Chedid; H. Ferrand; P. Chauvet; J. Lannoy; D. Beauvais; P. Martin-Pawlowski; C. Desprez; P. Kerschen; F. Gobert; B. Andorra; M. Dion; T. Perpoint; Y. Malek; F. Hubben; P. Dumez; B. Bouchacourt; Z. Poullet; V. Eiferman; A. Crepet; N. Cassir; M. Villessot; A. Tershiphorst; P. Prin; A. Formoso; L. Corti; E. Thomas; A. Simon; L. Taillandier; C. Biron; A. Seguin; C. Antier; B. Piron; M. Prime; C. Delaunay; M. Levraut; L. Inchiappa; P. Pereyra; Corazza; O. Thomel-Rocchi; M. Chiaruzzi; F. Villa; C. Tafani; L. Mokri; O. Lacatus; P. Tattevin; M. Revest; T. Nivet; F. Benezit; L. Armange; M. Leclercq; L. Picard; E. Le Tallec; B. Cador; S. Ardois; S. Belliard; A. Bachelot; M. El Acheck; M. Marc; J. Calmettes; C. Henry; E. Pappa; V. Hean; J.P. Camdessanche; A. Zilliox; Y. Boudard; S. Cunat; P. Perrin; B. Hoellinger; N. Douiri; N. Benmoussa; F. El-Bahri; S. Viguier; C. Rual; N. Vidal; P. Delobel; X. Boumaza; L. Mazet; S. Lagarrigue; A. Frelat; G. Gombert; J. Ciron; D. Biotti; M. Rafiq; M. Roussel; J. Pariente; B. Gachet; M Tetard; A. Meybeck; B. Cappeliez; G. Perrin; Y. Conan; O. Motica; M. Lacasse; L. Letranchant; Y. Bleher; D. Merrien; G. Vergne; N. Testard; R. CollotShow moreShow less
Affiliations
1. 1Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France; 2. 2Neo-I3D Research Group, Toulouse University Hospital, Toulouse, France; 3. 3Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Clinical Investigation Center 1436, Faculty of Medicine, Toulouse University Hospital, Toulouse, France; 4. 4Service de Médecine Intensive Réanimation à orientation neurologique, Sorbonne Université, Hôpital de la Pitié Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France; 5. 5OncoNeuroTox ICU Study Group, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France; 6. 6Department of Pharmacology, Clinical Investigation Center 1901, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France; 7. 7Unit of Neuroinfectious Rehabilitation, Department of Internal Medicine and Clinical Immunology, Bicêtre University Hospital, Le Kremlin-Bicêtre, Assistance Publique–Hôpitaux de Paris, Paris, France; 8. 8INSERM U1356, Gustave Roussy Institute, Villejuif, France; 9. 9Neurology Department, Sorbonne University, Paris Brain Institute, INSERM, CNRS, Pitié Salpetriere Hospital, APHP, Paris, France; 10. 10Department of Hematology and Immunology, Bicêtre Hospital, Paris-Saclay University, Assistance Publique–Hôpitaux de Paris, Le Kremlin-Bicêtre, France; 11. 11Department of Immunology, Toulouse University Hospital, Toulouse, France; 12. 12Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291, CNRS UMR5051, Toulouse University, Toulouse, France; 13. 13Cell Therapy Unit, Nancy University Hospital, Vandoeuvre-lès-Nancy, France; 14. 14Department of Virology, Toulouse University Hospital, Toulouse, France; 15. 15Department of Virology, Paris Cité University, Cochin Hospital, Paris, France; 16. 16Department of Neuroradiology, Toulouse University Hospital, Toulouse, France; 17. 17Department of Neuroradiology, Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France; 18. 18Department of Infectious Diseases, Sorbonne University, Assistance Publique–Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; 19. 19INSERM UMR-1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France; 20. 20Department of Infectious and Tropical Diseases, Croix Rousse University Hospital, Hospices Civils de Lyon, Lyon, France; 21. 21Service de Gériatrie, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Paris, France; 22. 22Service d’Hématologie Clinique et Thérapie Cellulaire, Centre de Recherche de Saint-Antoine, Sorbonne University, Hôpital Saint-Antoine, Assistance Publique–Hôpitaux de Paris, INSERM, UMRs938, Paris, France; 23. 23Department of Neurology, CHU Pellegrin, Bordeaux, France; 24. 24Department of Infectious and Tropical Diseases, CHU Gabriel Montpied, Clermont-Ferrand, France; 25. 25Unité de Greffe de Cellules Souches Hématopoïétiques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 26. 26Department of Neurology, University Hospital of Strasbourg, Strasbourg, France; 27. 27Strasbourg Neuroscience Institute, Strasbourg University, Strasbourg, France; 28. 28Institute of Genetics and Cellular and Molecular Biology, INSERM-U964, CNRS-UMR7104, University of Strasbourg, Illkirch-Graffenstaden, France; 29. 29Department of Infectious and Tropical Diseases, Quimper Hospital, Quimper, France; 30. 30Service de Maladies Infectieuses et Tropicales, Hôpital Necker-Enfants Malades, Université Paris Cité, Assistance Publique–Hôpitaux de Paris, Paris, France; 31. 31Department of Infectious Diseases, Tours University Hospital, Tours, France; 32. 32Department of Neurology, Toulon Hospital, Toulon, France; 33. 33Department of Internal Medicine, Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris, Paris, France; 34. 34Department of Hematology, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse University, Toulouse, France; 35. 35Hematology Unit, CHU Pitié-Salpêtrière, Sorbonne Université, Paris, France; 36. 36Médecine Intensive Réanimation, Hôpital de la Pitié-Salpêtrière, Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, FranceShow moreShow less
Source PDF DOI Publisher page
94 days

In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion

Authors
Susa Savukoski; Alina Maria Dettner; Anke Schultze; Christoph Gerber; Michael Stefan Steinberger; Rebecca Halbgebauer; Peter Melter; Arthur Dopler; Annette Palmer; Christian Karl Braun; Susanne Hafner; Bo Nilsson; Kristina Nilsson-Ekdahl; Tom Eirik Mollnes; Raban Heller; Hubert Schrezenmeier; Christoph Q. Schmidt; Markus S. Huber-Lang; Marco MannesShow moreShow less
Affiliations
1. 1Institute of Clinical and Experimental Trauma Immunology, Ulm University Medical Center, Ulm, Germany; 2. 2Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany; 3. 3Department for Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany; 4. 4German Center for Child and Adolescent Health, Partner Site Ulm, Ulm, Germany; 5. 5Department of Immunology, Genetics and Pathology, Rudbeck Laboratory C5:3, Uppsala, Sweden; 6. 6Linnaeus Centre of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden; 7. 7Department of Immunology, Oslo University Hospital, University of Oslo, Oslo, Norway; 8. 8Research Laboratory, Nordland Hospital, Bodo, Norway; 9. 9Department for Trauma Surgery, Orthopaedics, Reconstructive and Septic Surgery, and Sports Traumatology, German Armed Forces Hospital Ulm, Ulm, Germany; 10. 10Institute of Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Wuerttemberg-Hessen and University Hospital Ulm, Ulm, Germany; 11. 11Institute of Transfusion Medicine, University Hospital Ulm, Ulm, GermanyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Blood Advances take to review a manuscript?

As of 2026-11-19, CrushSCI has 6 complete review records for Blood Advances. The fastest paper went from submission to acceptance in 2 days (Gene therapy for sickle cell disease durability, received 2026-06-08, accepted 2026-06-10); the slowest took 98 days. The average is 52.8 days and the median is 54.5 days. The fastest record has an unusually short interval; please check the original source.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.